Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Jcr Pharmaceuticals Co. Ltd.
Headquarters: Ashiya, Hyogo, Japan
Website: http://www.jcrpharm.co.jp
Year Founded: 1975
Status: Public
Industry Sector: HealthTechnology
CEO: Shin Ashida
Number Of Employees: 934
Enterprise Value: $744,557,607
PE Ratio: -282.28
Exchange/Ticker 1: Tokyo:4552
Exchange/Ticker 2: N/A
Latest Market Cap: $417,034,947
BioCentury | Feb 28, 2025
Product Development
Rare Disease Spotlight: A genetic seizure disorder with a growing market, pipeline
As the first Dravet syndrome products establish the market, the pipeline moves toward selective small molecules and genetic therapies
BioCentury | Dec 20, 2024
Product Development
Long-awaited FDA approval for Mesoblast marks a first in the U.S.
Nearly a decade after Japanese approval, mesenchymal stromal cell therapy approved for pediatric GvHD
BioCentury | Apr 18, 2024
Product Development
Rare disease spotlight: a leukodystrophy with small pipeline behind first approval
At least three MLD programs are coming up behind Orchard’s Lenmeldy, although three others were recently discontinued
BioCentury | Mar 1, 2024
Product Development
Rare disease spotlight: enzyme replacement therapy for the brain
At least seven companies aim to overcome the challenge of delivering an enzyme across the blood-brain barrier to treat MPS IIIA
BioCentury | Oct 1, 2021
Finance
Sept. 30 Quick Takes: Advent closes €86M second fund
Data for Sanofi’s anti-OX40 mAb, plus TrialSpark’s $156M series C, Minerva’s next step toward schizophrenia submission and more
BioCentury | Jul 30, 2021
Distillery Therapeutics
In utero base editing may treat Mucopolysaccharidosis type I
DISEASE CATEGORY: Endocrine/Metabolic
INDICATION: Mucopolysaccharidosis In utero base editing could help treat mucopolysaccharidosis type I, a lethal lysosomal storage disease caused by a G to A
INDICATION: Mucopolysaccharidosis In utero base editing could help treat mucopolysaccharidosis type I, a lethal lysosomal storage disease caused by a G to A
BioCentury | May 20, 2021
Deals
Neuro deal flow: pharmas pinning hopes on new modalities, delivery technologies
The last three years of deals prioritize new modalities against known targets and CNS entry over discovery of new targets
BioCentury | May 13, 2019
Company News
May 13 Company Quick Takes: PeptiDream/JCR, Grail, Lilly, Onconova/HanX, Regeneron
BioCentury | Sep 1, 2018
Politics, Policy & Law
Stepping Through
How regulatory innovation lays the foundation for new business models
BioCentury | Jul 27, 2017
Strategy
FDA’s regeneration
What the regenerative medicine industry wants from FDA this September
Items per page:
1 - 10 of 73